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INTRODUCTION 
Fibro epithelial breast lesions are the most common breast 
abnormality in adolescent females referred to as fetal fibroadenoma, 
cellular fibroadenoma, juvenile fibroadenoma, giant fibroadenoma, 
fibroadenoma variant, tubular adenoma, hamartoma , phyllodes tumour. 
 The aetiology of the fibroepithelial lesions is found to be unclear. 
These are the benign conditions of the breast but some of them have the 
potential to turning into malignant. 
Among the breast lump benign disease of breast constitutes of 
80%.of these 7% are fibroadenoma and phyllodes tumour contributes to 
less than 1%. Even though the incidence is low, the importance of 
phyllodes tumour is that it is further divided by WHO into benign 
borderline and malignant, based on the stromal cellularity of atypical, 
stromal overgrowth, mitotic figures. So compared with fibroadenoma 
,phyllodes tumour  has more potential  for turning to malignancy. 
So the fibroadenoma requires a simple enucleation but for the 
phyllodes tumour, since it has more malignant potential, a wide excision 
is needed with a clearance of at least 1 cm. 
So when a patient with breast lump reaches the out-patient, we 
subject the patient with basic information and FNAC. Based on the 
FNAC report as fibroadenoma, we proceed with enucleation.post 
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operatively the histopathological examination of the specimen done. If 
the reports were found to be phyllodes tumour then we have to readmit 
the patient and post the patient for re-operation, which is the removal of 
excision biopsy site with clearance of about 1cm. 
This increase the morbidity to the patient and period of hospital 
stay of the patient is also increased. Secondly if the patient has lost follow 
up, then there is a high chance of reoccurrence of tumour and the patient 
will again present with breast lump over the excision biopsy site. 
To prevent the above mentioned difficulties, we need an 
investigation, which can pre-operatively distinguish a fibroadenoma and 
phyllodes tumour. 
Many studies have been undergone to differentiate the 
fibroadenoma and phyllodes tumour based on the clinical features, FNAC 
features, radiological features of mammography and USG.  
There are many scores that have been devised and studied to 
differentiate the fibroadenoma and phyllodes tumour, of which the 
Paddington’s clinicopathological suspicion score is of greater 
significance. So to determine the appropriate treatment, phyllodes tumour 
should be diagnosed pre-operatively. 
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AIMS AND OBJECTIVES 
1. To determine the incidence of fibroepithelial lesion in relation to 
age. 
2. To analyse and interpret the histological features in core needle 
biopsy to diagnose phyllodes tumour. 
3. To prevent re-operation and recurrence of tumour. 
4. To analyse and interpret core needle biopsy findings with the 
findings of clinical examination, mammography, 
ultrasonography, fine needle aspiration cytology in diagnosing 
phyllodes tumour. 
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REVIEW OF LITERATURE 
 
DEVELOPMENT OF BREAST 
The breast develops from the mammary ridge or milk line or line of 
Schultz, which is an ectodermal thickening. 
It develops at around 4th week of intrauterine life. 
The milk line extends from the axilla to groin, but in human beings 
most of them disappears except in the pectoral region. 
The stroma is mesodermal in origin. 
From the persisting parts, mammary pit develops; the floor of the 
mammary pit gives rise to secondary bud which divides further to form 
the lobes of the gland. 
The entire system is solid which later gets canalized. 
The nipple gets everted at the site of mammary pit. 
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ANATOMY OF BREAST 
Breast is one of the modified sweat gland. 
More precisely apocrine gland. 
It is present in the pectoral region. Both male and female found to 
have breast, but it is rudimentary in male, and well developed in female. 
 In the female reproductive system it forms an accessory organ. In 
the newborn it provides nutrition in the form of milk. Shape of female 
breast is due to the fat contained within the fibrous septa. 
Breast lies within the skin and pectoral fascia to which it is loosely 
attached. 
It extends from 2nd to 6th ribs and lateral border of sternum to mid- 
axillary line. 
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a prolongation of parenchymatous tissue, axillary tail runs upwards 
between the pectoralis major and latissimus dorsi muscles to blend with 
fat of axilla. 
The glandular tissue consists of 15 to 20 lobules (clusters of milk 
forming glands, also called as acini) which enters into branching and 
interconnected ducts. 
Just beneath the nipple the ducts enlarges as lactiferous sinus and 
then empty via the nipple opening. The secondary unit is a group of 
saccular alveoli draining into duct. 
 
The ducts of the alveoli are lined by single layer of epithelial cells. 
The ducts are surrounded by myoepithelial cells which were not found 
around the lobules. 
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The myoepithelial cells are contractile and helps to more secretion 
along the duct system. 
BLOOD SUPPLY OF BREAST 
ARTERIAL SUPPLY 
Breast is one of the extremely vascular organs.  
The branches of following arteries supply the mammary gland: 
1. Perforating branches of internal thoracic artery which is a branch of 
subclavian artery. 
2. Perforating branches of posterior intercostals arteries. 
3. Lateral thoracic, superior thoracic, acromio thoracic branches of 
axillary artery. 
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VENOUS SUPPLY OF BREAST: 
1. The veins follow the arteries.  
2. All veins converge towards the base of the nipple and form an 
anastomotic venous circle. 
3. From where veins run in superficial and deep veins.  
4. Superficial vein drains into internal thoracic vein.  
5. Deep vein drains into posterior intercostals, internal thoracic and 
axillary vein. 
 
Nerve supply of breast 
Mammary gland is supplied by anterior and lateral cutaneous 
branch of 4th to 6thintercoastalnerves 
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These nerve fibres are autonomic to blood vessels and smooth 
muscles and sensory fibres to skin. 
Milk secretion is not controlled by these nerves. 
 
Lymphatic of breast drains into following lymph nodes. 
Axillary lymph node which includes  
Anterior (pectoral group) 
Posterior group  
Lateral group 
Central group 
Apical group 
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1. Internal mammary (para sternal) nodes lies along the internal 
thoracic vessels  
2. Some of the lymphatics also reach the supra clavicular nodes, 
cephalic nodes, posterior intercoastal nodes. 
3. The lymphatic s of the breast divided into superficial and deep 
lymphatics. 
4. Skin of the breast except nipple and areola drains into superficial 
lymphatics. 
5. Parenchymal of breast, nipple and areola drain into deep 
lymphatics. 
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HISTOLOGY OF NORMAL BREAST: 
1. Breast has 
- 2  types of epithelial cells 
- 2 types of stroma 
- 2 main structures 
Epithelial cells: 
       Luminal cells 
Myoepithelialcells 
Stroma:  
        -Interlobular stroma 
        -Intralobar stroma 
Structure: 
Large ducts 
TDIU 
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NIPPLE: 
Covered by squamous  epithelium (pigmented). 
Near the nipple orifice majority of nipple have TOKER cells.  
Lactiferous sinus have serrated contour admixed with smooth 
muscles, collagen and elastic fibers. Basement membrane of  skin  
is continuous with basement membrane of duct. 
AREOLA; 
Pilosebaceous unit and hair present only at the periphery.  
Areola has numerous sensory nerve endings. 
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SKIN APPENDAGES: 
These are 
- Montgomrey tubercles. 
- Eccrine sweat glands and ducts. 
- Apocrine sweat gland and ducts. 
MAMMARIAN STROMA:  
             Divided into Interlobular stroma and  Intralobular stroma. 
PHYSIOLOGY OF BREAST 
 
At puberty growth of the mammary gland is caused by oestrogens. 
Secondary alveoli are stimulated by the progesterone and prolactin 
hormone from hypophysis cerebri 
1. Benign disease of the breast  
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2. Congenital and developmental abnormalities  
3. Amastia- total lack of breast tissue 
4. Athlelia- absence of nipple  
5. Polythelia–supernumerary nipples 
6. Polymastia – supernumerary breast 
7. When polymastia is present in the women, the additional breast 
tissue can secrete milk when nipple is present. 
GYNAECOMASTIA 
Gynecomastia is the growth is glandular tissue in male breast. It is a 
benign condition account s for more than 65% of male breast 
abnormalities. It is usually unilateral and occurs in Young man. bilateral 
gynecomastia is due to systemic cause. 
CAUSES OF GYNECOMASTIA 
Physiological causes 
 Neonatal gynecomastia 
 Pubertal gynecomastia 
 Senile gynecomastia 
 
 
15 
 
 
Pathological causes 
 Anorchia 
 Klinefelter's syndrome 
 Bilateral cryptorchidism 
 Mumps 
 Irradiation 
 Hypopituitarism 
 Isolated gonadotropin deficiency 
 Endocrine tumours 
 Alcoholic cirrhosis 
 Hemochromatosis 
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Treatment of gynecomastia: 
 For physiological causes reassurance is all  what is needed 
 Stop drugs causing gynecomastia. 
 Subcutaneous mastectomy in trouble some cases.(Webster’s 
procedure) 
 Liposuction- assisted mastectomy 
DUCT ECTASIA 
- It is a widening of a ducts 
- It is more common in women’s In Their 40s and 50s. 
- The most common symptom is nipple discharge which is usually 
gray to green in colour. 
- Tenderness and redness of nipple and surrounding breast tissue 
may also be present. 
- Microscopically – the peri ductal elastic tissue is destroyed and 
the surrounding tissue is infiltrated with lymphocytes and plasma 
cells. 
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Treatment 
Small volume discharge managed conservatively. 
Socially embarrassing discharge is treated by major duct excision. 
Galactocele: 
Cystically dilated terminal ductules that are filled with milk and 
lined by double layer of breast epithelium and myoepithelium.  
Classically appears as a painless lump weeks to months after cessation of 
breast feeding. It is probably formed by obstruction to a duct in the 
purpaerium. The milk retained proximal to the obstruction eventually 
become cheese like. 
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The common complications of this type of swelling are infection. 
 
The treatment is by surgical excision 
 Intraductal papilloma  
 This benign lesions of the lactiferous duct wall occurs centrally 
beneath the areola in 75% of cases 
 They most commonly produce a bloody nipple discharge, 
something associated with pain. 
 They are solitary proliferation of ductal epithelium 
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Intra ductal papilloma s should be treated by excision of a duct as a 
wedge resection. 
FIBROADENOMA 
Fibroadenomas are benign tumours composed of stromal and epithelial 
elements. The tumours are commonly seen 
In young  women. 
Fibroadenoma is a common well - circumscribed lesion of the breast & 
develop in the breast prior to menopause. 
Pericanalicular tumors usually being found below the age of 30 
&intracanalicular tumors there after. 
Either breast may be affected and multiple & successive  tumors may 
develop in the same or contra-Lateral  breast. 
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• The preicanalicular tumor forms a firm discrete  mass, which is 
freely mobile in the breast  tissue, hence the name (BREAST 
MOUSE ) 
• The intracanalicular tumors tend to be softer and may grow to 
such size that there is necrosis of the overlying skin. To such a 
condition the terms serocystic disease of bordie OR cystosarcoma  
phylloides OR Giant fibroadenoma have been given.  However 
despite the implication of malignancy in the later term, the 
tumour is benign.  
 
 
 
21 
 
 
Pathophysiology: 
• Fibroadenomas are benign tumours that represent a hyper plastic or 
proliferative process in a single terminal ductal unit; their 
development is considered to be an aberration of normal 
development. The cause is unknown. Approximately 10% of 
fibroadenomas disappear each year, and most stop growing after 
they are 2-3 cm in size. 
• Fibroadenomas may involutes in postmenopausal women, and 
coarse calcifications may develop. 
• Conversely, the tumours may grow rapidly during  pregnancy, 
during hormone replacement therapy, or  during 
immunosuppression, in which case they can  simulate malignancy. 
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• Fibroadenoma variants include juvenile fibroadenoma, which 
occurs in female adolescents. 
• This swelling has been  variously regarded as a  simple hyperplasia 
of  epithelial and / or  connective tissue  elements or as a  
composite neoplasm of  the breast in which the  epithelial & 
mesenchymal  components grow  simultaneously  
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CLINICAL FEATURES:  
• On clinical examination, fibroadenomas may be nonpalpable or 
palpable, oval, freely mobile, rubbery masses. Their size varies 
from smaller than 1 cm in diameter to as large as 15 cm in diameter 
in the giant forms.  
• Most commonly, the tumours are removed surgically when they 
are 2-4 cm in diameter. In young women, the tumours are usually 
palpable. In older women, the tumours typically appear as a mass 
on mammograms, and the tumour may be palpable or nonpalpable.  
• The size of fibroadenomas also can vary during the menstrual cycle 
and during pregnancy. 
• In the postmenopausal period, tumours regress and often  develop 
calcifications  
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Types 
- Solitary 
- Few (< 5 / breast ) 
- Multiple (> 5 / breast ) 
- Giant (> 4 / 5 cms) & Juvenile 
Natural history 
- Majority remain small & static  50% involutes spontaneously 
- No future risk of malignancy 
Investigation 
- Breast, fibroadenoma Sonogram. Demonstrates a hypo echoic 
mass with smooth partially lobulated margins that is typical of a 
fibroadenoma. 
- Breast, fibroadenoma, Craniocaudal mammograms obtained 1 
year apart demonstrates a newly developing mass in the outer part 
of the breast. 
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TREATMENT 
Reassurance of the patient Excisional biopsy 
The natural history of these lesions has recently been elucidated 
and has resulted in a change in management policy.  
Over a 2 year period approximately 20% slowly increase in size, 
10% reduce in size, 20% completely resolve and 50% remain static.  
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With knowledge of this natural history a conservative management 
policy can often be adopted.  
In those <35 years and with a triple assessment supporting the 
diagnosis then observation with regular review is acceptable.  
In those > 35 years and in younger patients requesting it, excision 
biopsy should be considered.  
CYSTOSARCOMA PHYLLODES (CSP) 
This is one of the rare conditions, found predominantly as benign 
tumour that occurs almost only in the female breast. The name 
cystosarcoma phyllodes were derived from the Greek words sarcoma, 
which means fleshy tumour, and phyllo, means leaf. 
Gross appearance shows characteristics of a large,  malignant 
sarcoma, that takes  a leaf like appearance when cross  sectioned, and it 
shows epithelial cyst like spaces when  seen histologically (hence the 
name phyllodes). 
The most common tumours is benign, so the name is misleading. 
But now the   terminology used is phyllodes tumor. 
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PATHOPHYSIOLOGY OF CSP 
Pathophysiology: 
Phyllodes tumour is the common nonepithelial neoplasm that 
occurs in female breast. 
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Clinically presents as a sharply demarcated, smooth texture and 
freely movable mass. It presents as large tumour, and the average size is 
more than 5 cm. Some lesions are also more than 30 cm in size that have 
been reported. 
TREATMENT: 
Surgical Care: 
The preferred surgery is wide local excision with a rim of normal 
tissue of about 1cm of clearance. 
If the tumour to the breast ratio is sufficiently high to provide a 
satisfactory cosmetic appearance by segmental excision or total 
mastectomy, followed by with or without flap reconstruction, is an 
alternative. 
Radical procedures are usually not warranted. If clinically suspicious 
nodes present then lymph node dissection is to be done. Mostly all of 
these nodes are reactive and they do not have malignant cells in them. 
FIBROCYSTIC DISEASE 
- Commonest lesions of female breast are fibrocystic disease. 
- Two common descriptions are Cystic lobular hyperplasia & 
fibrocystic disease of the breast. 
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- Cystic hyperplasia is nothing but a variant of normal changes of 
the breast that occur with menstruation. 
- Usually presents bilaterally.  
- It is most painful in the premenstrual period 
-  Benign condition of breast has varying Incidence, in relation to 
age. 
- Of which 20% are Menstruating age group. 
- Of the premenopausal age group it constitutes 30-50%. 
- The other names are mammary dysplasia, Cystic disease, Cyclic 
Mastopathy, Cystic Hyperplasia. 
Path physiology of fibrocystic disease: 
- The cause is mostly unknown Hormonal basis. 
- Of the hormones Oestrogen , Progesterone and Prolactin 
- Thyroid  Methylexanthiones   
- The causative was considered to be Oestrogen predominance over 
progesterone. 
- High Oestrogen levels in the Luteal phase was shortened  
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- Progesterone levels are reduced to 1/3 normal. So the females 
having progesterone deficiency are at a fivefold high risk of 
premenopausal breast cancer. 
- 70% due to Corpus Luteal Deficiency and  Anovulation. 
- Pre Menstrual Tension syndrome is risk factors.  
Prolactin- 
 Increased in about 1/3 of women most    probably due to the 
dominance of Oestrogen in pituitary. 
Thyroid – 
Low levels sensitize epithelium of mammary gland to Prolactin. 
Methylexanthiones- 
High intake of coffee, tea, cold drinks chocolate is a high risk. 
Path morphology 
Proliferation of the connective and epithelial tissues are stimulated 
by oestrogen. 
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The polymorphism of fibrocystic disease is: 
- Fibrosis  
- Formation of cyst,   proliferation of epithelial cells,  
- Atrophy of the lobular-alveoli  
- Course of fibrocystic disease 
- It represents a clinical problem presents in approximate 30% of 
patients.  
Predominantly found in,  
-  Abnormal menstrual cycle   
-  Nulliparous women  
- Spontaneous abortions history 
- oral contraceptives nonusers 
- early menarche  
-  Late menopause.  
-  Most present in their mid 30s and 40s.  
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There are three phases clinically,  
 Phase I - Stromal fibrosis which is moderate, just started 
hardness in the breast tissue and tenderness in premenstrual 
breast  
 Phase II – Increased  fibrosis causing increased  hardening and 
tenderness, formation of cyst, nodularity 
 Phase III - Fibrosis is more Pronounced and tenderness, 
formation of macro cyst. 
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DIAGNOSIS OF FIBROCYSTIC DISEASE 
Triple Assessment 
Symptoms and Signs - 
- Many months to several years of history. 
- Ovulating women, multiparous women, and patients using oral 
contraceptives rarely presents with fibrocystic disease. 
- Tenderness of breast is observed in most of the patients. 
- Irregular menses, dysmenorrhoea,  menometrorrhagia, or ovarian 
cysts are found to be associated in 40% to 60% 
Nipple secretion- 
Spontaneous discharge or secretion can be expelled from the 
nipple. Cytological features are amorphous material (fat, proteins), ductal 
cells, erythrocytes, and / or foam cells. Straw yellow, greenish, or bluish 
coloured fluid present. 
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TREATMENT OF FIBROCYSTIC DISEASE 
MEDICAL 
Goal- 
- Progression should be stopped 
-  For relieving  pain 
- To   Soften breast tissue 
Indicated when- 
- FDB not increasing in  size 
- Nipple discharge not present 
- Psychological  effect ont present 
Surgical-                                                                                          
Indicated when- 
- Size is progressively increasing 
- Discharges that are Serous / Serosanguineous / bloody. 
- disturbed  psychology 
MEDICAL- 
Hormones 
OC pills- 
- They are  protected from  FBD 
-   High potency of Progestogen 
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Progestogens- 
- Have to be started  in the luteal  phase for a period of 9-12 
months 
- Of which 80% get relief and have to  restart the therapy in 40%  
Danazol- 
- One of the  most  effective therapy 
- Basis are the ovarian suppression 
- 200-600mg/day is the usual dosage. 
Medical- 
- This is one of the ineffective modalities 
- Diet therapy- Restriction of caffeine 
- Diuretics 
- Agents that containing iodine. 
- Thyroid hormone ,Evening Primrose oil  Vitamin E & B6  
Dihydroergotamine and  Antiprolactin drugs 
Surgical treatment- 
- In most severe cases, surgical removal of lumps can be done. 
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CLINICAL EXAMINATION 
The patient is examined in the following posture: 
1. Arms by the side of body and patient sitting 
2. Arms raised above head  
3. Hands over hips alternatively contraction and releasing. 
4.  Patient leaning forward 
5. Lying posture 
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INSPECTION:  
Inspection of the patient in sitting posture arms by the side of her body: 
1. Breast 
- Position compared with opposite Brest 
- Site 
- Shape 
- Any mass  
- Ulcer 
2. Skin over the breast 
- Dilated veins 
- Dimple 
- Puckering 
- Retraction  
- Peau'dOrange 
- Nodules 
- Ulceration 
- Fumigation 
3. Nipple 
- Presence 
- Position 
- Number 
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- Size 
- Shape 
- Discharge 
4. Areola 
- Colour 
- Size 
- Surface 
5. Arm and forearm 
- Edema 
- Nodules 
6. Axilla 
7. Supraclavicular fossa 
- Inspection of the patient with arms raised above the head: 
- Look for 
- Peau d' Orange 
- Fixity 
- Retraction of nipple 
- Inspection on leaning forward: 
- Fixity to chest wall  
- Inspection on Contraction and relaxing pectoralis major: 
- Swelling becomes prominent or not 
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PALPATION: 
Palpate systemically from areola, concentrically outwards. 
1. Local temperature and tenderness 
2. Swelling : 
- Number 
- Site  
- Size  
- Shape 
- Margins 
- Consistency 
- Fluctuations 
- Tenderness 
3. Fixity to skin 
4. Fixity to chest wall 
5. Intrinsic mobility 
Examination of nipple:  
1. retraction  
2. Crackles 
3. Discharge 
Examination of axillary lymph node: 
- All groups should be examined separately.  
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MAMMOGRAPHY 
- Low voltage, high ampere x-rays 
- 300 mA and 40ky exposed  
- This is one technique of taking x-rays known as seems strahlung 
type x-rays 
- Delivers radiation of 0 1cGy per study by comparison chest x ray 
delivers only 25% of this dose 
- Sensitivity increases with the age as the breast tissue becomes less 
dense.(used in age more than 40 years) 
Two views: 
- Craniofacial 
- Mediolateral oblique view 
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INDICATION 
- Age greater than 50 years 
- Age greater than 40 years with risk factors 
- Already operated one side 
- If we plan for can conservative surgery, then we have to rule out 
multimodal involvement. 
- Mammography guided biopsy 
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Rounded borders with lobulated appearance in mammography are 
more in favour of the phyllodes tumour 
BIRADS Staging: 
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ULTRASOUND 
- It is an adjuvant to mammography  
- Many interventional procedures in breast lesions can be done under 
its guidance 
- It differentiate solid masses from cystic masses 
- A linear 7mhz array transducer is used, but transducer up to 10 to 
13 MHz can be used most preferably. 
Benign Lesions Look Like  
- hyper or hypo echogenic 
- Shape of ellipsoid 
- Well circumscribed margins 
- Malignant lesions look like 
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- Margins are irregular 
- Hypoechoic to surrounding tissue 
- Posterior acoustic shadow present 
- Vertical growth appearance. 
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FINE NEEDLE ASPIRATION CYTOLOGY 
INTRODUCTION 
FNAC is a technique where a thin bore needle is used to obtain 
cells from a lesion and smears done, for cytopathological diagnosis.  
This basis of this technique is that the tumor cells are less cohesive 
and can be aspirated easily.  
Using this technique we can diagnose the breast lumps, thyroid 
nodules, liver disease, subcutaneous soft tissue mass, salivary gland 
diseases and oral diseases.  
This is very helpful in the lesions of oral cavity which is very 
vascular, and an open biopsy can cause bleeding which becomes difficult 
to control.  
FNAC solves these problems, by using a 10 ml Syringe with which 
adequate material can easily be obtained, from an intraoral or extra oral 
site without any discomfort to the patient. There will be no risk of 
bleeding.  
A subsequent surgery may not needed in some cases and patient 
can be planned for appropriate treatment.  
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Reports of FNAC can be prepared within 24 hours of sampling. It 
gives early, rapid information to the surgeon about the  lesion the surgeon 
dealing  with. 
 
HISTORICAL PERSPECTIVE 
Martin  and Ellis introduced this technique  in  1930 in the United 
States, but it never became  widespread.  
Since the 1950s it has been used extensively in  Scandinavia and in 
Holland.  
Fine Needle for aspiration were first introduced in  1950 in Europe 
by Lopez-Cardozo in the  Netherlands and Soderstrom in Sweden  
Publication of the Zajicek from Karolinska Hospital present in 
Stockholm that brought aspiration cytology to the level of international 
alterations.  
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ADVANTAGE 
- Simple outpatient technique  
- fast diagnosis  
- cost effective 
- multiple sites can be sampled  in the one sitting  
- diagnostic accuracy  is very high 
Many other test such as bacterial culture, immunocytochemistry, 
flow cytometry, cytogenetics, polymerase chain reaction,etc. are possible 
from FNAC material. 
LIMITATIONS 
-  Tissue architecture is lost. 
-  We cannot detect Capsular invasion and lymphovascular 
invasions. 
- In situ versus invasive carcinoma is difficult to differentiate. 
- Good training is needed for correct  interpretation of results. 
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 IN CLINICAL INVESTIGATION 
It was first used as a mean for confirming a clinical suspicion  of 
local recurrence or  distant metastasis of known cancer, so that further 
surgical intervention may not be needed. 
It is also used in Inflammation, infection, degenerative
 conditions, in diagnosis and monitoring  of graft rejection 
transplantation surgery  
This can be used as an Alternative to frozen section  
Per operative cytology  can be done. 
Successful reporting of FNAC depends on four fundamental 
requirements: 
- Representative samples from  the lesion  should be obtained. 
- Adequate sample size  in terms of cells and other  tissue 
components should be obtained. 
- Correct smearing and processing  of sample should be done.  
- With correct clinical/radiological information biopsy should be 
obtained.  
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EQUIPMENTS NEEDED: 
1. NEEDLES:  22-23 gauge needle.  
2. Syringes: 20 ml syringe  
3. Pistol handle- as shown below for negative suction: 
 
4. Sterile container: Physiological saline or Hank’s  balanced 
solution as preservative. 
5. Slides: clean, dry & free of dirt and grease.  
6. Haemocytometer cover slip of 0.4mm gives better  control on 
smearing pressure and a proper  spread.  
7. Fixatives: 70-90% ethanol, Carnoy’s fixative, 10%  buffered 
formalin, gluteraldehyde can be used.  
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8. Stains- to differentiate various structures. 
9. Microscopes –for viewing the slides 
TECHNIQUE OF FINE NEEDLE ASPIRATION:  
There are 2 techniques:  
1. FNAC with aspiration  
2. FNAC without aspiration  
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FNAC WITH ASPIRATION 
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Steps: 
-Biopsy site should be  cleaned by spirit and betadine.  
-The swelling is gently palpated and needle is introduced   and is 
moved in a to and fro fashion. When this act is performed a gentle 
negative suction  is also created by withdrawing the piston.  
-on a slide, the aspirated material is expelled  
-The  smearing is done, by gently pressure by pressing the upper  
slide on the lower one. 
-Following this, air is taken into the syringe and needle hub is 
reattached to the syringe. 
FNAC without aspiration: 
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- Zajdela introduced this technique in 1987.  
- He devised based on the fact  that the capillary pressure that has 
been generated  in a  fine needle is sufficient enough to keep the 
separated  cells inside the  lumen of the needle.  
CAUSES OF FAILURE TO OBTAIN A REPRESENTATIVE  
SAMPLE: 
- The target tissue has been missed by the needle while taking the 
samples.  
- Needle has entered the lesion where cystic/necrotic/hemorrhagic 
area present which are devoid of diagnostic cells.  
- Needle may have entered a dominant benign mass and have 
missed a small nearby malignant lesions.  
- Fibrotic/desmoplastic  tissue yield a scant amount of cells.  
 SAMPLE PROCESSING: 
A clean & dry  microscope slide are used in which the sample are 
expelled and smearing done. 
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SMEARING 
DIRECT – 
DRY 
Dry smearing can be done if the sample is creamy in consistency 
and   consists of large amount of cells suspended in the background of 
small amount of tissue fluid. 
WET 
Wet smearing is done when there are smaller number of cells which 
are  suspended in fluid or  blood. 
- Indirect smearing is done: samples obtained  are   processed by 
centrifugation.  
- Other alternative technique are Millipore nucleopore filtration and  
Thin prep technique  
FIXATION & STAINING 
FNAC uses two techniques:  
- Simple Air drying which is followed by staining with a  
haematological stain such as MAY GRUNWALD-  GIEMSA 
STAIN , Jenner-Giesma, Diff-Quik  
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- Alcohol fixation and then followed by staining according to PAP 
or  with H&E.  
COMPLICATIONS 
- Usually there are no complications  
- Some of the complications are Bleedings, hematoma, emphysema 
(in lung).  
- One of the Rare complication is anaphylactic reaction due to 
accidental  rupture of hydrated cyst.  
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CORE NEEDLE BIOPSY 
It is a procedure in which a chunk of tissue is removed using 
specialised device, in contrast to fine needle  aspiration cytology in which 
the individual cells are aspirated with syringe. 
- More reliable than cytology. 
- Less invasive  than surgical biopsy. 
- Allows planning of therapy. 
Disadvantages are:  
- More expensive than cytology. 
- More invasive than cytology. 
Indication: 
1. As a first approach : 
- Large lesions clearly malignant at imaging (when future treatment 
is neo-adjuvant therapy. 
- When there is no palpable mass but micro calcifications are 
present. 
2. After fine needle aspiration cytology: 
- When results are Inconclusive. 
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- When the findings are different between clinical ,radiological and  
cytology 
- Stereotactic - guided vacuum assisted core biopsy. 
- Conventional true –cut biopsy. 
Choice of needle: 
 
Core needle biopsy is usually done with 14G needle but 
ultrasonograpy guided core needle biopsy can be done with smaller 
needle of size 16G/18G. 
Advantages of smaller needle: 
- They are sharper and can penetrate more easily through firm dense 
breast tissue. 
- Bleeding risk is minimal. 
- Local anaesthesia or skin incision are not required. 
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PROCEDURE: 
Under aseptic precaution patient in supine position parts painted 
and draped, the swelling  of interest is palpated and fixed, a small nick is 
made using 11 size blade. Using a conventional or self retained gun 
swelling is entered and biopsy done. 
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Processing: 
- At least 3 hematocilin and eosin stained sections are cut attained 
interval of 50mirons. 
- Specimens are radio graphed to look for micro calcification. 
- Fibroepithelial lesions are categorised under B3. In UK BSP 
category. 
- ER ,PR and  HER 2 status can be accessed in core needle biopsy. 
- Core needle biopsy accurately identifies of more than 90% cases of 
benign and malignant disease. 
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METHODOLOGY 
 
STUDY DESIGN: Prospective co-hort study. 
SAMPLE SIZE: n= 40 
INCLUSION CRITERIA: Patient’s who are satisfying the 
PADDINGTON’S clinico-pathological suspicion score in department of 
surgery, CMCH during the period of JAN 2017 to DEC 2017 are 
included in to the study. 
PADDINGTON’S CLINICOPATHOLOGICAL SCORE 
 
Patient’s with score of >2 are included in this study. 
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EXCLUSION CRITERIA: 
- Invasive malignant breast tumour. 
- Immunocompromised state. 
- Coagulation disorders. 
OUT COME: 
Phyllodes tumour is diagnosed to pre –operatively using core 
needle biopsy. 
Recurrence and re-operation of tumour is reduced. 
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RESULTS 
 
The collected data were analysed with IBM.SPSS statistics 
software 23.0 Version .To describe about the data descriptive statistics 
frequency analysis, percentage analysis were used for categorical 
variables and the mean & S.D were used for continuous variables. The 
Receiver Operator Characteristic (ROC) curve analysis was used to find 
the Sensitivity, Specificity ,PPV and NPV on comparison of efficacy of 
the tools with Histopathology .To find the significance in categorical data 
the  Fisher's Exact was used. In all the above statistical tools the 
probability value .05 is considered as significant level.  
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SITE OF OCCURRENCE OF TUMOUR: 
TABLE 1:SITE OF OCCURRENCE OF TUMOUR: 
Site Frequency Percent 
Left 14 35.0 
Right 26 65.0 
Total 40 100.0 
 
From the above tabular column, the frequency of lesion occurring over 
right is found to be on the higher side. Of the 40 patients studied, 26 
presented with lesion over right side and 14 over the left side. The 
percentage of occurrence over right is 65% and of the left is 35%. 
 
  
Site
Left Right
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DURATION OF THE PRESENTATION OF LUMP: 
TABLE 2:DURATION OF THE PRESENTATION OF LUMP: 
Duration Frequency Percent 
Upto 10 days 4 10.0 
11 - 20 days 19 47.5 
21 - 30 days 11 27.5 
Above 30 days 6 15.0 
Total 40 100.0 
 
From the above tabular column, most of patients have the duration of the 
lesion between 11 to 20 days, of the percentage of about 47.5%, which 
constitutes about 19 patients. About 11 patients have the duration 
between 21 to 30 days, constitutes a percentage of 27.5%.very less 
number of patients presents less than 10 days and more than 30 days. 
Descriptive Statistics 
 
N Minimum Maximum Mean 
Std. 
Deviation 
Duration 40 10 60 22.85 12.601 
Valid N (list wise) 40 
    
 
The mean duration of presentation among the 40 patients included in 
study is 22.85 and a standard deviation of 12.601. 
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AGE OF PRESENTATION: 
TABLE 3:  AGE OF PRESENTATION: 
AGE RANGE Frequency Percent 
Up to 20 yrs 8 20.0 
21 - 40 yrs 28 70.0 
41 - 60 yrs 4 10.0 
Total 40 100.0 
 
From the above tabular column, the frequency of occurrence of 
fibroepithelial lesions are more in 21 to 40 years of age, which accounts 
for about 70% of patients. Up to 20 years and more than 40 years the 
percentage of occurrence is 20% and 10% respectively. 
Duration
Upto 10 days 11 - 20 days 21 - 30 days Above 30 days
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The following graph shows the age distribution of fibroepithelial 
lesions,  
 
SIZE OF THE LESION: 
TABLE 4:SIZE OF THE LESION: 
Size Frequency Percent 
2 3 7.5 
3 9 22.5 
4 7 17.5 
5 15 37.5 
6 6 15.0 
Total 40 100.0 
 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
Upto 20 yrs 21 - 40 yrs 41 - 60 yrs
Age distribution
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From the above tabular column, most of the lesions have 5 cm of 
diameter, which accounts for 15 patients, of percentage of 37.5%. About 
9 patients have a size of 3cm which constitutes about 22.5%. 7 cases have 
a size of 4cm, of a percentage of 17.5%.6 cases have a size of 6cm, of a 
percentage of 15%. 
 
 
  
Size Percent
2
3
4
5
6
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MAMMOGRAPHIC FINDINGS: 
Table 5 : MAMMOGRAPHIC FINDINGS: 
Mammography findings Frequency Percent 
Yes 22 55.0 
No 18 45.0 
Total 40 100.0 
 
From the above tabular column, mammographic findings of suspicion of 
phyllodes tumour is found in 22 patients which constitutes about 55%. 
Case Processing Summary 
Mammogaphy Valid N (listwise) 
Positivea 22 
Negative 18 
 
Area Under the Curve 
Test Result Variable(s): Histopathology 
Area 
Std. 
Error 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.639 .089 .135 .465 .812 
 
On comparing with the results of histopathology of excised specimen. 
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The area under the curve is 0.639. 
- Sensitivity- 73.33 
- Specificity-56.00 
- PPV-50.00 
- NPV-77.78 
- Accuracy -64.67 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
3.259a 1 .071 
  
Continuity 
Correctionb 
2.182 1 .140 
  
Likelihood Ratio 3.357 1 .067 
  
Fisher's Exact 
Test    
.104 .069 
Linear-by-Linear 
Association 
3.178 1 .075 
  
N of Valid Cases 40 
    
 
From the above tabular column, the p value of the mammographic 
findings is more than .05 which shows there no significant co- relation of 
mammographic findings to phyllodes tumour. 
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ULTRASONO GRAPHY: 
TABLE 6:USG FINDINGS: 
USG finding Frequency Percent 
Yes 24 60.0 
No 16 40.0 
Total 40 100.0 
 
From the above table USG findings suggestive of phyllodes tumour is 
found in 24 cases, constitutes a percentage of 60%. 
Case Processing Summary 
USG Valid N (listwise) 
Positive 24 
Negative 16 
 
Area Under the Curve 
Test Result Variable(s): Histopathology 
Area 
Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.708 .083 .027 .546 .871 
  
 
 
71 
 
On comparing with the results of histopathology of excised specimen. 
- Area under the curve- 0.708 
- Sensitivity- 86.67 
- Specificity- 56.00 
- PPV-54.17 
- NPV-87.50 
- Accuracy -71.33 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
7.111a 1 .008 
  
Continuity 
Correctionb 
5.444 1 .020 
  
Likelihood Ratio 7.764 1 .005 
  
Fisher's Exact Test 
   
.010 .008 
Linear-by-Linear 
Association 
6.933 1 .008 
  
N of Valid Cases 40 
    
 
From the above tabular column the p value of USG Findings is  equal to 
0.01,which shows that there is a significant correlation of USG findings 
to phyllodes tumour which is statistically significant. 
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FNAC: 
TABLE 7:FNAC FINDINGS: 
FNAC Frequency Percent 
PT 6 15.0 
F 34 85.0 
Total 40 100.0 
 
From the above tabular column, of the 40 patients 34 have FNAC 
findings in favour of fibroadenoma, 6 to phyllode tumour which 
contributes to 85% and 15% respectively. 
Case Processing Summary 
FNAC Valid N (list wise) 
Positivea 6 
Negative 34 
 
Area Under the Curve 
Test Result Variable(s): Histopathology 
Area Std. Errora 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.868 .057 .004 .756 .979 
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On comparing with the results of histopathology of excised specimen. 
- Area under the curve-0.868 
- Sensitivity-40.00 
- Specificity-100.00 
- PPV-100.00 
- NPV-73.53 
- Accuracy -70.00 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
11.765a 1 .001 
  
Continuity 
Correctionb 
8.837 1 .003 
  
Likelihood Ratio 13.626 1 .000 
  
Fisher's Exact 
Test    
.001 .001 
Linear-by-Linear 
Association 
11.471 1 .001 
  
N of Valid Cases 40 
    
 
From the above tabular column the p value of FNAC is less than 0.01 
which is highly statistically significant and there is a significant 
correlation of FNAC finding to phyllodes tumour. 
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CORE NEEDLE BIOPSY: 
TABLE 8: CORE NEEDLE BIOPSY FINDINGS: 
Core needle biopsy Frequency Percent 
PT 16 40.0 
F 24 60.0 
Total 40 100.0 
 
From the above tabular column, out of the 40 patients core needle biopsy 
diagnosed 16 cases of phyllodes tumour, constitutes a percentage of 40%. 
The rest 60% (i.e) 24 patients were diagnosed as fibroadenoma. 
The diagnosis by core needle biopsy is based 4 features, 
- epithelial fragments  
- stormal fragments 
- mitotic figures 
- spindle cells 
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TABLE 9: EPITHELIAL FRAGMENTS: 
Epithelial Fragments Frequency Percent 
Few 8 20.0 
Many 32 80.0 
Total 40 100.0 
 
From the above table, 80% of patients have many epithelial fragment and 
20% have few fragments, of about 32 and 8 patients respectively. 
 
 
  
Epithelial Fragments
Few Many
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Number Frequency Percent 
Few 21 52.5 
Many 19 47.5 
Total 40 100.0 
 
From the above table, 47.5%of patients have many stormal fragment and 
52.5% have few fragments, of about 19 and 21 patients respectively. 
 
TABLE 10: CELLULARITY: 
Cellularity Frequency Percent 
1+ 17 42.5 
2+ 13 32.5 
3+ 10 25.0 
Total 40 100.0 
 
From the above table, 42.5% of patients have 1+ cellularity that comprise 
of 17 patients, 32.5% have 2+ and 25% have 3+celularity. This 
constitutes about 13 and 10   patients respectively. 
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TABLE 11: SPINDLE CELLS: 
Spindle Cells Frequency Percent 
Negative 22 55.0 
Positive 18 45.0 
Total 40 100.0 
 
 
From the above table, 45% of patients have spindle cells that constitutes 
18 patients and  rest 55% spindle cells are absent which comprise of 22 
patients. 
Cellularity
1+ 2+ 3+
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TABLE 12: MITOTIC FIGURES: 
Mitotic Figures Frequency Percent 
High 10 25.0 
Low 30 75.0 
Total 40 100.0 
 
 
From the above table, 75% of patients have low  mitotic figures that 
constitutes 30 patients and the rest 25% have high mitotic figures that 
constitutes 10 patients. 
Spindle Cells
Negative Positive
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Case Processing Summary 
core needle biopsy Valid N (listwise) 
Positivea 16 
Negative 24 
 
Area Under the Curve 
Test Result Variable(s): Histopathology 
Area 
Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.917 .054 .0005 .810 1.000 
 
Mitotic Figures
High Low
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On comparing with the results of histopathology of excised specimen 
- Area under the cuve-0.917 
- Sensitivity-93.33 
- Specificity-92.00 
- PPV-87.5 
- NPV-95.83 
- Accuracy -92.67 
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Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson  
Chi-Square 
28.444a 1 .000 
  
Continuity 
Correctionb 
25.000 1 .000 
  
Likelihood Ratio 32.555 1 .000 
  
Fisher's Exact Test 
   
.0005 .000 
Linear-by-Linear 
Association 
27.733 1 .000 
  
N of Valid Cases 40 
    
 
From the above tabular column the P value of the core needle biopsy is 
less 0.01 which shows that core needle biopsy  is highly significant in 
diagnosing phyllodes tumour. 
On comparing the detection percentage of fibroadenoma and phyllodes 
tumour by various tool the following tabular column is obtained, 
 
Mammography USG FNAC 
Core needle 
biopsy 
Histopathology 
PT 55.0 60.0 15.0 40.0 37.5 
F 45.0 40.0 85.0 60.0 62.5 
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The same is explained in the graph 
 
TABLE 13:PROCEDURE DONE: 
Procedure Done Frequency Percent 
Enucleation 24 60.0 
Wide Excision 16 40.0 
Total 40 100.0 
 
From the tabular column, based on the pre operative diagnosis   60% of 
cases have undergone enucleation and rest 40% have undergone wide 
excision, which constitutes 24 and 16 patients respectively. 
  
0%
20%
40%
60%
80%
100%
Outcomes of the various tools
PT F
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The following explains the above 
 
 
So to detect the diagnostic efficacy of core needle biopsy,we 
compare the ROC curve of mammographic findings, usg findings,FNAC 
findings with the standard gold standard results of histopathology of 
excised specimen. 
 
Case Processing Summary 
Histopathology Valid N (listwise) 
Positivea 15 
Negative 25 
 
  
Procedure Done
Enucleation Wide Excision
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Area Under the Curve 
Test Result 
Variable(s) 
Area 
Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper Bound 
Mammography .647 .090 .124 .470 .823 
USG .713 .083 .025 .551 .876 
FNAC .700 .093 .036 .517 .883 
Core needle  
biopsy 
.927 .049 .0005 .830 1.000 
 
P - Value ** Highly Significant at P ≤ .01 
 
P - Value * Significant at 0.01 < P ≤ .050 
 
P -Value # No Significant at P >.050 
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So on comparing the area under the curve of mammographic 
findings,USG findings,FNAC findings and core needle biopsy findings 
,the core needle biopsy  is found to be the most significant tool in 
detecting the phyllodes tumour. The area under the curve of 
mammographic findings, USG findings , FNAC findings and core needle 
biopsy findings are 0.647,0.713,0.700,0.927 respectively, in which core 
needle biopsy has highest area under curve. The p-value also 0.0005 for 
core needle biopsy which is highly significant. 
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CONCLUSION 
To conclude, though the incidence of phyllodes tumour is very 
less, it has a potential for turning into malignant. So pre-operative 
diagnosis of  phyllodes tumour is essential as it decides the line of 
management, which is a simple enucleation for fibroadenoma and wide 
excision for phyllodes tumour. Fibroadenoma is a benign condition which 
has clinical findings, radiological findings, FNAC findings similar to that 
of phyllodes tumour so the differentiation between fibroadenoma and 
phyllodes tumour becomes difficult, so we use core needle biopsy of the 
lesion and we analyse 4 features which are the epithelial fragments, 
stormal fragments, spindle cell and mitotic figures to differentiate the 
phyllodes tumour and fibroadenoma.   
 As the core needle biopsy is an invasive procedure we select the 
high risk patients using paddington’s clinicopathological suspicion score 
and subject those patients to core needle biopsy. By these analysis we can 
pre operatively diagnose the phyllodes tumour. So we can decide the 
correct line of management pre operatively, which is the wide excision of 
tumour. This prevents the recurrence and re-operation following initial 
line of management. So that morbidity to the patient can be reduced. So 
core needle biopsy can be used as a effective tool to preoperatively 
diagnose phyllodes tumour. 
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PROFORMA 
 
NAME: 
AGE: 
SEX: 
IP.No: 
CLINICAL FINDINGS: 
MAMMOGRAPY FINDINGS: 
ULTRASONOGRAPY FINDINGS: 
FINE NEEDLE ASPIRATION CYTOLOGY REPORT: 
CORE NEEDLE BIOPSY REPORT: 
 PRE-OPERATIVE DIAGNOSIS: 
PROCEDURE DONE: 
HISTO-PATHOLOGICAL EXAMINATIN REPORT: 
  
 
 
92 
 
xg;g[jy; gotk;  
 
nehahspapd; bgah;  :     njjp : 
taJ / ghypdk;  :  
cs;nehahsp vz;  : 
neha;f;Fwp  :     
 -------------------------------------------------------------------------------------------- Mfpa ehd; 
ehsJ njjpapy; nfhit kUj;Jtf; fy;Y}hp kUj;Jtkidapy; khh;gf 
fl;o mWit rpfpr;irf;fhf mDkjpf;fg;gl;Ls;nsd;.  
 khh;gf fl;oapd; jd;ik Fwpj;J Muha rij ghpnrhjid 
vLf;fg;gLk; vd;Wk;/ mjd; Kot[f;F Vw;g mWitapd; jd;ik 
Vw;gLk; vd;gJk; kUj;Jtuhy; bjhptpf;fg;gl;lJ.  
 ,j;jpR ghpnrhjid vdJ rpfpr;irapd; juj;ij 
cah;j;Jtjw;fhfnt vd;gija[k;/ 
 ,jd; fhuzkhf vdJ rpfpr;irapy; fhyjhkjk; Vw;glhJ 
vd;gija[k;/  
 Ma;t[ Kot[fspd; ,ufrpak; fhf;fg;gLk; vd;gJk;/  
 ghpnrhjid Kot[fs; Ma;t[f;F cl;gLj;jg;gLk; vd;gJk;/  
 ehd; tpUk;gpdhy; vg;bghGJ ntz;LkhdhYk; Ma;tpypUe;J 
tpyfpf; bfhs;syhk; vd;gija[k; kUj;Jth; \yk; bjhpe;J 
bfhz;nld;.  
,tw;iw KGikahfg; g[hpe;J bfhz;L KGkdJlDk;/ Raepidt[lDk;/ 
vt;tpj eph;ge;jKk; ,d;wp ghpnrhjidf;Fk;/ rpfpr;irf;Fk;/ Ma;t[f;Fk; 
xj;JiHg;g[ ju rk;kjpf;fpnwd;. 
 
,lk; :  
njjp :  
nehahspapd; ifbahg;gk;  
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CORE NEEDLE BIOPSY 
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Histopathology of 
Excised Specimen Epithelial 
Fragments  
Stormal Fragments 
Sp
in
dl
e 
C
el
ls 
M
ito
tic
 
Fi
gu
re
s 
Number  Cellularity 
1 Meena  24 125530 10 R 5 N N F Many  Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
2 Soundariya  17 127592 14 R 2 Y N F Few Many  1+ - Low Fibroadenoma Enucleation Fibroadenoma 
3 Pushpharani  40 119054 50 L 5 Y Y PT Many  Many  2+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
4 Gunavathivel  34 128100 14 R 3 N Y F Many  Few 1+ + Low Fibroadenoma Enucleation Fibroadenoma 
5 Pechiyammal  35 120322 60 R 4 N Y F Many  Many  3+ + Low Phyllodes Tumour Wide Excision Phyllodes Tumour 
6 Saraswathy  45 120359 20 L 3 N Y F Many  Many  2+ + Low Phyllodes Tumour Wide Excision Phyllodes Tumour 
7 Rajeswari  60 127569 30 R 3 Y Y F Many  Many  1+ - Low Fibroadenoma Enucleation Fibroadenoma 
8 Lavanya  30 127890 15 R 4 N N F Few Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
9 Geetha  38 123036 30 R 5 Y Y F Many  Few 1+ + Low Fibroadenoma Enucleation Phyllodes Tumour 
10 Aarthi  19 128537 40 R 5 Y N F Few Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
11 Sumathi  33 123653 15 R 6 Y Y PT Many  Many  3+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
12 Vaneeshwari  25 129654 45 R 5 N Y F Many  Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
13 Chithra  35 135453 10 L 6 N N F Many  Many  2+ + High  Phyllodes Tumour Wide Excision Fibroadenoma 
14 Ayyammal  36 131041 50 R 3 Y Y F Many  Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
15 Parameswari  34 119295 25 L 5 Y Y PT Many  Many  3+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
16 Brindha 20 131765 14 R 6 N N F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
17 Shamala 34 131489 14 R 3 Y N F Few Few 1+ + Low Fibroadenoma Enucleation Fibroadenoma 
18 Jomiveimma 20 125036 20 R 4 Y Y PT Many  Many  3+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
19 Pushphalani 40 123536 21 R 4 N Y F Many  Many  3+ + Low Phyllodes Tumour Wide Excision Phyllodes Tumour 
20 Sowbakiya  17 89992 30 L 5 N Y F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
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21 Pavithra 20 43151 18 R 2 Y Y F Many  Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
22 Prabhavathy  25 126476 28 L 3 Y Y F Many  Many  3+ + Low Phyllodes Tumour Wide Excision Phyllodes Tumour 
23 Vasanthi  40 106478 21 R 4 Y N F Many  Many  2+ - High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
24 Saradha 40 105486 14 L 5 N Y F Many  Many  2+ + Low Phyllodes Tumour Wide Excision Phyllodes Tumour 
25 Rajeswari  29 100676 10 L 6 N N F Few Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
26 Krishnaveni  35 102036 15 L 4 Y Y PT Many  Many  3+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
27 Vinmathi  23 10784 21 R 5 Y N F Many  Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
28 Indirarani  29 121996 14 L 2 N Y F Few Many  1+ - Low Fibroadenoma Enucleation Fibroadenoma 
29 Kowsalya  17 122263 14 R 5 N N F Many  Many  2+ + High  Phyllodes Tumour Wide Excision Fibroadenoma 
30 Minorani  28 121999 30 R 3 Y Y F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
31 Kamala  45 101100 14 R 4 Y N F Many  Many  3+ + Low Phyllodes Tumour Wide Excision Phyllodes Tumour 
32 Nirmala  28 1260684 14 R 6 N N F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
33 Ramya 22 114266 10 L 3 Y N F Many  Few 2+ - Low Fibroadenoma Enucleation Fibroadenoma 
34 Vaishali  24 115649 30 R 5 N Y F Few Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
35 Rangammal  32 124844 45 R 3 Y Y F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
36 Ponvalli  19 129553 21 R 5 Y Y PT Many  Many  3+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
37 Pandijveni  23 132364 14 L 5 N N F Few Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
38 Rathinammal  48 125889 20 R 5 Y Y F Many  Many  3+ + High  Phyllodes Tumour Wide Excision Phyllodes Tumour 
39 Johnbharathi  37 1132932 20 L 5 Y N F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
40 Mumtaj 39 125689 14 L 6 N Y F Many  Few 1+ - Low Fibroadenoma Enucleation Fibroadenoma 
 
